The Technical Analyst
Can-Fite Biopharma Ltd [CANF]
Exchange: AMEX Sector: Healthcare Industry: Biotechnology
Can-Fite Biopharma Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.87% $2.03
America/New_York / 2 mai 2024 @ 15:19
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 11.13 mill |
| EPS: | -3.00 |
| P/E: | -0.680 |
| Earnings Date: | May 30, 2024 |
| SharesOutstanding: | 5.48 mill |
| Avg Daily Volume: | 0.0178 mill |
| RATING 2024-05-02 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.680 | sector: PE -4.07 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.680 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.147 (-107.24%) $-2.18 |
| Date: 2024-05-02 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.851 - 2.21 ( +/- 8.82%) |
| ATR Model: 14 days |
Forecast:
16:00 - $2.03
Live Trading Signals (every 1 min)
Forecast
1: 15:29 - $2.02
Forecast 2: 16:00 - $2.03
Forecast 3: 16:00 - $2.03
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.03 (-2.87% ) |
| Volume | 0.0109 mill |
| Avg. Vol. | 0.0178 mill |
| % of Avg. Vol | 61.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CANF
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CANF
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Latest Press Releases
2024-04-25 07:00:00 - Press Release
Long-term Complete Response To Can-fite's Namodenoson In Patient With Advanced Liver Cancer: Article Published In A Leading Scientific Journal
Petach tikva, israel--(business wire)---- $canf--can-fite biopharma ltd. (nyse american: canf) (tase: canf), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it published an article in the experimental and therapeutic medicine journal, titled “long-term complete response to namodenoson in liver cancer with child-pugh b cirrhosis: a case report” (link). the patient participated in the phase ii liver cancer.
2024-04-15 07:00:00 - Press Release
Can-fite: Scientific Article Published By Kol Presents Namodenoson As A Promising Drug Candidate To Treat Advanced Liver Cancer And Mash
Petach tikva, israel--(business wire)---- $canf--can-fite biopharma ltd. (nyse american: canf) (tase: canf), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that biomedicines published an article titled “namodenoson at the crossroad of metabolic dysfunction-associated steatohepatitis (mash) and hepatocellular carcinoma (hcc)”. biomedicines is a highly reputable journal that publishes articles on clinical.
2024-04-03 07:00:00 - Press Release
Can-fite: Submits Fda With An Ind Application To Conduct Phase Iib Clinical Trial Of Namodenoson In Mash Patients
Ramat gan, israel--(business wire)---- $canf--can-fite biopharma ltd. (nyse american: canf) (tase:canf), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced submission of an investigational new drug (ind) application to the u.s. food and drug administration (fda) for the treatment of metabolic dysfunction-associated steatohepatitis (mash), also known as non-alcoholic steatohepatitis (nash), for the company's.
2024-04-01 07:00:00 - Press Release
Can-fite Biopharma, Ltd. To Present At The Ld Micro Invitational Xiv
Ramat gan, israel--(newsfile corp. - april 1, 2024) - can-fite biopharma, ltd. (nyse american: canf) announced today that it will be presenting at the 14th annual ld micro invitational at the sofitel new york on april 8th-9th, 2024.
2024-03-28 07:00:00 - Press Release
Can-fite Reports 2023 Financial Results And Clinical Update
Ramat gan, israel--(business wire)---- $canf--can-fite biopharma ltd. (nyse american: canf) (tase: canf), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended december 31, 2023. recent clinical & development milestones achieved namodenoson drug candidate: ewopharma recently acquired marketing rights for namodenoson in the treatment of pancr.
Latest News
2024-04-01 07:00:00 - Newsfile Corp
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024.
2023-11-22 09:01:29 - Zacks Investment Research
Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson
Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.
2023-11-21 11:01:02 - PennyStocks
3 Top Penny Stocks To Watch Before Next Week
As retail investors seek explosive returns, penny stocks remain enticing potential opportunities capable of massive short-term gains. However, the considerable risks of these cheap equities also highlight the need for due diligence.
2023-10-27 07:31:44 - Zacks Investment Research
New Strong Buy Stocks for October 27th
MTRX, OPI, CANF, ENLV and RAIL have been added to the Zacks Rank #1 (Strong Buy) List on October 27, 2023.
2023-07-07 07:00:00 - Business Wire
Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory, and liver diseases, today announced it has been invited to present at the Emerging Growth Conference on Thursday, July 13, 2023 at 11:25 AM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with Can-Fite.
2023-06-14 13:28:08 - Zacks Investment Research
Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer
Can-Fite's (CANF) shares rise 11.4% as it reveals its plans of submitting an investigational new drug application. The idea is to initiate expansion studies for namodenoson to treat pancreatic carcinoma.
2023-05-10 13:41:32 - Zacks Investment Research
All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy
Can-Fite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-05-02 13:12:16 - MarketBeat
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
Can-Fite BioPharma Ltd. NYSEAMERICAN: CANF is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction.
2022-07-26 14:00:30 - Zacks Investment Research
All You Need to Know About CanFite Biopharma Ltd (CANF) Rating Upgrade to Buy
CanFite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2022-06-29 07:57:01 - Benzinga
Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial
Can-Fite BioPharma Ltd (NYSE: CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis. The study data show that patients treated with oral Piclidenoson 2 mg or 3 mg twice daily had clinically.